ZA926837B - A pharmaceutical composition for and a method of using a combination of an uricosuric agent and an EAA antagonist - Google Patents

A pharmaceutical composition for and a method of using a combination of an uricosuric agent and an EAA antagonist

Info

Publication number
ZA926837B
ZA926837B ZA926837A ZA926837A ZA926837B ZA 926837 B ZA926837 B ZA 926837B ZA 926837 A ZA926837 A ZA 926837A ZA 926837 A ZA926837 A ZA 926837A ZA 926837 B ZA926837 B ZA 926837B
Authority
ZA
South Africa
Prior art keywords
combination
pharmaceutical composition
uricosuric agent
eaa antagonist
antagonist
Prior art date
Application number
ZA926837A
Other languages
English (en)
Inventor
Christopher Franklin Bigge
Graham Johnson
Charles Price Taylor Jr
Devind Franklin Welty
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA926837B publication Critical patent/ZA926837B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA926837A 1991-09-09 1992-09-08 A pharmaceutical composition for and a method of using a combination of an uricosuric agent and an EAA antagonist ZA926837B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75640191A 1991-09-09 1991-09-09

Publications (1)

Publication Number Publication Date
ZA926837B true ZA926837B (en) 1994-03-08

Family

ID=25043303

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA926837A ZA926837B (en) 1991-09-09 1992-09-08 A pharmaceutical composition for and a method of using a combination of an uricosuric agent and an EAA antagonist

Country Status (16)

Country Link
US (4) US5407935A (fr)
EP (1) EP0603301B1 (fr)
JP (1) JP3218038B2 (fr)
AT (1) ATE162075T1 (fr)
AU (1) AU660717B2 (fr)
CA (1) CA2115442C (fr)
DE (1) DE69224069T2 (fr)
DK (1) DK0603301T3 (fr)
ES (1) ES2113957T3 (fr)
GR (1) GR3026369T3 (fr)
MX (1) MX9205127A (fr)
NO (1) NO307645B1 (fr)
NZ (1) NZ244243A (fr)
PT (1) PT100850B (fr)
WO (1) WO1993004688A1 (fr)
ZA (1) ZA926837B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2113957T3 (es) * 1991-09-09 1998-05-16 Warner Lambert Co Preparacion farmaceutica conteniendo un agente uricosurico y un antagonista de aminoacidos excitadores.
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
WO1998003541A1 (fr) 1996-07-22 1998-01-29 University Of Utah Research Foundation Conantokines
JP2002513380A (ja) 1996-07-22 2002-05-08 コグネティックス・インコーポレイテッド コナントキンの使用
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
NZ508414A (en) * 1998-05-26 2003-12-19 Carlen Peter Louis Compositions and methods for alleviating impaired mental function, memory loss and reducing recovery time in anaesthetized mammals
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US7799794B2 (en) 2000-06-28 2010-09-21 Merck Sharp & Dohme Corp. Treatment for cardiovascular disease
US7276514B2 (en) * 2002-05-15 2007-10-02 Charitable Leadership Foundation - Medical Technology Acceleration Program Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof
US20080051428A1 (en) * 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
WO2005092442A2 (fr) * 2004-03-22 2005-10-06 Apkarian Vania A Methode et compositions de traitement de douleurs neuropathiques chroniques
US8461223B2 (en) 2005-04-07 2013-06-11 Aspen Aerogels, Inc. Microporous polycyclopentadiene-based aerogels
ITFI20050083A1 (it) * 2005-04-29 2006-10-30 Univ Firenze Uso dell'acido chinurenico per la prevenzione e il trattamento dello shock
JP2008545627A (ja) 2005-05-09 2008-12-18 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 腎結石症を治療する方法
WO2007140293A2 (fr) 2006-05-25 2007-12-06 Aspen Aerogels, Inc. Compositions d'aérogel présentant une efficacité amélorée
EP2338492A1 (fr) 2009-12-24 2011-06-29 Universidad del Pais Vasco Procédés et compositions pour le traitement de la maladie d'Alzheimer
WO2012033941A1 (fr) 2010-09-10 2012-03-15 Takeda Pharmaceuticals North America, Inc. Méthodes de traitement simultané à base de théophylline et de fébuxostat
US10806711B2 (en) 2011-08-12 2020-10-20 University Of Cincinnati Method of treating acute decompensated heart failure with probenecid
EP2968238A1 (fr) 2013-03-13 2016-01-20 University of Cincinnati Traitement d'un dysfonctionnement cardiaque diastolique avec un agoniste de récepteur trpv2
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
EP3427729A1 (fr) * 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probénécide destiné à être utilisé dans le traitement de maladies, troubles ou états épileptiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812458A (en) * 1986-09-16 1989-03-14 A/S Ferrosan 6,7-disubstituted-2,3-dihydroxyquinoxaline compounds, pharmaceutical compositions thereof, and their use as neuroleptics
DK146787A (da) * 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
DK0501378T3 (da) * 1991-02-28 1995-03-20 Merrell Dow Pharma NMDA-antagonister
ES2113957T3 (es) * 1991-09-09 1998-05-16 Warner Lambert Co Preparacion farmaceutica conteniendo un agente uricosurico y un antagonista de aminoacidos excitadores.

Also Published As

Publication number Publication date
GR3026369T3 (en) 1998-06-30
PT100850A (pt) 1993-10-29
NO940809L (no) 1994-03-08
NO307645B1 (no) 2000-05-08
NZ244243A (en) 1995-07-26
WO1993004688A1 (fr) 1993-03-18
EP0603301A1 (fr) 1994-06-29
PT100850B (pt) 1999-07-30
NO940809D0 (no) 1994-03-08
CA2115442A1 (fr) 1993-03-18
US5767119A (en) 1998-06-16
US5407935A (en) 1995-04-18
CA2115442C (fr) 2003-09-23
ATE162075T1 (de) 1998-01-15
US5627168A (en) 1997-05-06
MX9205127A (es) 1993-07-01
DE69224069D1 (de) 1998-02-19
AU2594392A (en) 1993-04-05
DE69224069T2 (de) 1998-07-02
US5942513A (en) 1999-08-24
AU660717B2 (en) 1995-07-06
DK0603301T3 (da) 1998-09-14
ES2113957T3 (es) 1998-05-16
JPH06510544A (ja) 1994-11-24
JP3218038B2 (ja) 2001-10-15
EP0603301B1 (fr) 1998-01-14

Similar Documents

Publication Publication Date Title
ZA926837B (en) A pharmaceutical composition for and a method of using a combination of an uricosuric agent and an EAA antagonist
PT705100E (pt) Guanidinas substituidas terapeuticas
EA200100572A1 (ru) Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии
UA48946C2 (uk) Арилалкілдіазинони, спосіб їх одержання (варіанти), фармацевтичний склад, спосіб його одержання та спосіб лікування
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
FI941826A (fi) Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
MX9602818A (es) Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
UA41355C2 (uk) Засіб для лікування нейро-сніду
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
ATE171935T1 (de) 2-amino-4-phenyl-4-oxo-buttersäure-derivate mit kynureninase und/oder kynurenin-3-hydroxylase inhibierender wirkung
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
MY104521A (en) Treatment of depression.
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
EA199600048A2 (ru) N,n-диэтил-8,8-дипропил-2-азаспиро[4,5]декан-2-пропанамин дималеат, фармацевтическая композиция на его основе и способ индуцирования иммуномодуляции
HUP9903685A2 (hu) Olanzapin alkalmazása túlzott agresszivitás kezelésére szolgáló gyógyszerkészítmények előállítására
ATE254919T1 (de) Verwendung von penciclovir zur behandlung von menschlichem herpes virus-8
EP0796105A4 (fr) Compositions pharmaceutiques destinees au traitement de maladies auto-immunes et comprenant l'oligomere b de la toxine de pertussis ou ses sous-unites
DE69429538D1 (de) Verwendung von 2-aminopurinderivaten zur behandlung und prophylaxe der menschlichen herpesvirus 6 infektionen
RU93035807A (ru) Способ лечения юношеского эпифизиолиса
DK8893D0 (da) Medicament for treatment or prevention of disease
ZA931010B (en) Method of treating abnormal tissue proliferation by administering an angiotensin II antagonist